AssetMark Inc’s AnaptysBio ANAB Stock Holding History

AssetMark Inc’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43K	Hold	36	–	–	﹤0.01%	2917
2026 Q1	$2K	Hold	36	–	–	﹤0.01%	2856
2025 Q4	$1.75K	Hold	36	–	–	﹤0.01%	2802
2025 Q3	$1.1K	Hold	36	–	–	﹤0.01%	2761
2025 Q2	$799	Buy	+36	New	+$754	﹤0.01%	2655

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

AssetMark Inc's ANAB Position: Q2 2026 in Review

AssetMark Inc held its AnaptysBio (ANAB) position steady in Q2 2026 at 36 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #2917.

AssetMark Inc first reported a position in ANAB in Q2 2025 and has held it in 5 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

AssetMark Inc held 36 shares of AnaptysBio worth $2.43K as of Q2 2026.
AssetMark Inc left its AnaptysBio share count unchanged in Q2 2026.
AnaptysBio made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2917 holding.
AssetMark Inc first reported a position in AnaptysBio in Q2 2025 and has held it in 5 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.